Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Alvesco; Alvesco HFA; BTR-15; BTR-15K; BY 9010; Ciclesonide DPI; Ciclesonide I.S.; Ciclesonide pMDI; EL 876; Omnair; Omnaris; Omnaris HFA; RPR 251526; TBN-15; XRP 1526; Zetonna

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer Covis Pharma; Sunovion Pharmaceuticals; Takeda; Takeda Pharmaceuticals International GmbH; Teijin Pharma
  • Class Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma; Perennial allergic rhinitis; Seasonal allergic rhinitis
  • Phase III COVID 2019 infections

Most Recent Events

  • 22 May 2020 The US FDA approves IND application for ciclesonide in COVID-2019 infections
  • 19 May 2020 Phase-III clinical trials in COVID-2019 infections in USA, United Kingdom, Australia, South Korea, Sweden (Inhalation) (NCT04377711)
  • 11 May 2020 Covis Pharma plans a phase III trial for COVID-19 infection (In children, In adolescents, In adults, In the elderly) in May 2020 (NCT04377711)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top